HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

For Estee Lauder Companies, COVID-19 Has Changed Everything And Nothing

Executive Summary

Lauder’s business has been thrashed by COVID-19, but the firm is encouraged that its biggest growth drivers before the crisis are the same ones carrying it through.

You may also be interested in...



Estee Lauder Companies, Among Industry’s ‘Long COVID’ Cases, Lowers FY 2024 Outlook

The Estee Lauder Companies says Asia travel retail will hammer fiscal 2024 full-year net sales, now expected to be down 2% to up 1%. A new profit recovery plan is designed to drive $800m-$1bn of incremental operating profit over the next two fiscal years, the New York-based firm said on 1 November.

Estee Lauder Eliminating Up To 2,000 Heads As It Rationalizes Brick-And-Mortar, Reinvests Online

Lauder’s online business grew at a near triple-digit organic rate in the fiscal 2020 fourth quarter, and the firm intends to go on investing resources accordingly. The firm’s fiscal 2020 net sales slipped 4% to roughly $14.3bn, reported, due to COVID-19 effects.

COVID-Crunched Cosmetics Shoppers Spending Less, Trading Down, Wary Of Stores

Recent surveys from consulting, retail analytics and e-commerce logistics firms support the views of leading beauty and personal-care companies that are modifying their approaches in light of consumers’ changing means and preferences during COVID-19.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel